[Three studies in type 2 diabetes: ADOPT Rosiglitazone monotherapy in type 2 diabetes: what indication?].
Roussel
R
R
Service endocrinologie, diabétologie, nutrition, CHU Bichat Claude Bernard, 46 rue Henri Huchard, 75722 Paris 18. ronan.roussel@gmail.com
D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000009:adverse effects
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone